We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Across the recent three months, 4 analysts have shared their insights on Generation Bio (NASDAQ:GBIO), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Generation Bio ( (GBIO)) has issued an ...

Wedbush analyst David Nierengarten on Wednesday downgraded Generation Bio (GBIO) to ‘Neutral’ from ‘Outperform’ with a $7 price target after the company announced a strategic restructuring. Shares of ...

• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of ...

CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune ...

CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co (GBIO). (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune ...

Generation Bio (GBIO) presented data on its cell-targeted lipid nanoparticle – ctLNP – and immune-quiet DNA – iqDNA – platforms at the European Society of Gene and Cell Therapy 31st Annual Congress.

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find the cash to take its lipid nanoparticle tech into the clinic. The Massachusetts-based company has ...

Generation Bio said Geoff McDonough is resigning as president and chief executive. The board named Yalonda Howze as interim president and CEO. She has served as the company's chief legal officer since ...

After Generation Bio telegraphed plans to lay off 90% of its staff this summer, Xoma Royalty has come knocking to bring yet another ailing biotech into its fold. Xoma, which styles itself as a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generation Bio, which once ...